The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma

A. U. Magomedova, S. K. Kravchenko, A. M. Kremenetskaya, E. E. Zvonkov, E. A. Baryakh, O. V. Margolin, I. B. Kaplanskaya, I. A. Vorobyev, R. S. Samoilova, T. N. Obukhova, T. N. Moiseeva, E. E. Zybunova, E. G. Gemdigyan, A. I. Vorobyev

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Aim. To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS). Material and methods. A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005. The diagnosis was made by WHO criteria. Results. A complete remission was achieved in 76.9% patients. Resistance to therapy was observed in the patients with bone marrow affection. The 2.5-year overall survival was 74%, 2-year event-free survival was 75% (the events were recurrence and resistance). Follow-up continued from 5 to 47 months. Conclusion. The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.

Original languageEnglish
Pages (from-to)44-47
Number of pages4
JournalTerapevticheskii Arkhiv
Volume78
Issue number10
Publication statusPublished - Dec 11 2006

Keywords

  • Chemotherapy
  • Diffuse large B-cell lymphosarcoma
  • Survival

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma'. Together they form a unique fingerprint.

Cite this